Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4165967 | 0.86 | KDM4E (0.42) | SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Bromide SCHEMBL4880840 | 0.85 | CYP3A4 (0.41) | SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4573822 | 0.85 | CA12 (0.48) | SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| Alcohol SCHEMBL5566652 | 0.83 | CA12 (0.46) | SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4170737 | 0.83 | CA12 (0.39) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL6214346 | 0.82 | SMN1; SMN2 (0.51) | SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5254676 | 0.81 | CYP3A4 (0.39) | SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4163641 | 0.81 | CYP3A4 (0.49) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| Bromide SCHEMBL7554050 | 0.80 | CYP3A4 (0.48) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5264841 | 0.79 | CA2 (0.37) | SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1491542-B1 | Intermediate compounds for the preparation of imidazo-pyridine-derivatives | ASTRAZENECA AB (SE) | 2007-09-05 | — | — | EP | claimed |
| EP-1105391-B1 | Imidazo[1,2-a]pyridine compounds that inhibit gastric acid secretion, pharmaceutical compositions thereof, and processes for thier preparation | ASTRAZENECA AB (SE) | 2004-10-27 | — | — | EP | claimed |
| US-20090247755-A1 | Process for Preparing a Substituted Imidazopyridine Compound | ELMAN BJORN | 2009-10-01 | — | — | US | disclosed |
| US-20090247755-A1 | Process for Preparing a Substituted Imidazopyridine Compound | ELMAN BJORN | 2009-10-01 | — | — | US | disclosed |
| US-20090247755-A1 | Process for Preparing a Substituted Imidazopyridine Compound | ELMAN BJORN | 2009-10-01 | — | — | US | disclosed |
| EP-1491542-B1 | Intermediate compounds for the preparation of imidazo-pyridine-derivatives | ASTRAZENECA AB (SE) | 2007-09-05 | — | — | EP | disclosed |
| US-20060063797-A1 | Process for preparing a substituted imidazopyridine compound | ELMAN BJORN | 2006-03-23 | — | — | US | disclosed |
| EP-1073657-B1 | IMIDAZO PYRIDINE DERIVATIVES WHICH INHIBIT GASTRIC ACID SECRETION | ASTRAZENECA AB (SE) | 2005-12-07 | — | — | EP | disclosed |
| US-6900324-B2 | Process for preparing a substituted imidazopyridine compound | ASTRAZENECA AB (SE) | 2005-05-31 | — | — | US | disclosed |
| EP-1317455-B9 | PROCESS FOR PREPARING A SUBSTITUTED IMIDAZOPYRIDINE COMPOUND | ASTRAZENECA AB (SE) | 2004-11-17 | — | — | EP | disclosed |
| EP-1105391-B1 | Imidazo[1,2-a]pyridine compounds that inhibit gastric acid secretion, pharmaceutical compositions thereof, and processes for thier preparation | ASTRAZENECA AB (SE) | 2004-10-27 | — | — | EP | disclosed |
| EP-1317455-B1 | PROCESS FOR PREPARING A SUBSTITUTED IMIDAZOPYRIDINE COMPOUND | ASTRAZENECA AB (SE) | 2004-08-04 | — | — | EP | disclosed |
| US-20040039013-A1 | Process for preparing a substituted imidazopyridine compound | ASTRAZENECA AB (SE) | 2004-02-26 | — | — | US | disclosed |
| EP-1317455-A1 | PROCESS FOR PREPARING A SUBSTITUTED IMIDAZOPYRIDINE COMPOUND | AstraZeneca AB (SE) | 2003-06-11 | — | — | EP | disclosed |
| WO-2002020523-A1 | PROCESS FOR PREPARING A SUBSTITUTED IMIDAZOPYRIDINE COMPOUND | ASTRAZENECA AB (SE) | 2002-03-14 | — | — | WO | disclosed |
| US-6313137-B1 | FOR THERAPY AND PROPHYLAXIS OF GASTROINTESTINAL INFLAMMATORY DISEASES | ASTRAZENECA AB (SE) | 2001-11-06 | — | — | US | disclosed |
| EP-1073657-A1 | IMIDAZO PYRIDINE DERIVATIVES WHICH INHIBIT GASTRIC ACID SECRETION | AstraZeneca AB (SE) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999055706-A9 | IMIDAZO PYRIDINE DERIVATIVES WHICH INHIBIT GASTRIC ACID SECRETION | ASTRA AB (SE) | 2000-03-16 | — | — | WO | disclosed |
| WO-1999055706-A1 | IMIDAZO PYRIDINE DERIVATIVES WHICH INHIBIT GASTRIC ACID SECRETION | ASTRAZENECA AB (SE) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063797-A1 | Process for preparing a substituted imidazopyridine compound | NISCH, CYP1B1, CYP1A2 | SMN1; SMN2 2455/4885CYP1A2 3/4885CYP3A4 8/4885 |
| US-20090247755-A1 | Process for Preparing a Substituted Imidazopyridine Compound | NISCH, CYP1A2, CYP1B1 | SMN1; SMN2 2481/4885CYP1A2 2/4885CYP3A4 13/4885 |
| US-20040039013-A1 | Process for preparing a substituted imidazopyridine compound | CYP1B1, BRD1, SKP1 | SMN1; SMN2 2736/4885CYP1A2 10/4885CYP3A4 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.